The Gut Bacteria Byproduct Scientists Now Link to Alzheimer’s Disease

If you have been digging into why gut health keeps coming up alongside Alzheimer's risk, you already know most of the science has stayed vague about the actual mechanism. A new study narrows that gap considerably. Researchers have traced a specific compound made by bacteria living in the human gut directly to worsened brain damage in both people and mice. The compound, called imidazole propionate (ImP), was already known to raise the risk of diabetes and cardiovascular disease. This is the first study to follow ImP from the bloodstream into the brain itself and show what it does once it gets there.

Key Takeaways

• A gut bacteria byproduct called imidazole propionate (ImP) was linked to lower cognitive scores and Alzheimer's biomarkers in a study of 1,196 adults.
• A genetic variant that raises ImP levels was also tied to modestly higher Alzheimer's risk, and in mice, ImP directly worsened amyloid buildup, tau damage, and leakiness in the brain's blood vessels.
• The biggest caveat is that every mouse experiment used only male mice, and there is currently no diet, supplement, or consumer test that acts on this finding.

Gut Bacteria Make a Compound Called Imidazole Propionate

Imidazole propionate (ImP) is a small molecule produced when certain gut bacteria break down histidine, an amino acid found in protein-rich foods, using an enzyme called urocanate reductase (UrdA). Researchers at the University of Wisconsin-Madison, publishing in Nature Communications, found that people with higher blood levels of ImP scored measurably lower on cognitive tests and carried worse levels of brain-damage biomarkers, years before any diagnosis. The team then gave the compound to mice and watched it directly worsen Alzheimer's-like damage, connecting "gut bacteria are associated with Alzheimer's" to a specific, testable mechanism.

Why This Matters if You're Watching Your Own Alzheimer's Risk

Anyone managing a family history of Alzheimer's, or already tracking risk factors like high blood pressure or type 2 diabetes, has a new item worth knowing about, because ImP was already linked to insulin resistance years before this study connected it to the brain. A 2020 follow-up found ImP is elevated in people with prediabetes and diabetes across multiple European countries, and it has separately been tied to high blood pressure, hardened arteries, and chronic kidney disease. People managing any of those conditions, or with a parent who developed Alzheimer's or another dementia, are the groups this finding speaks to most directly, since ImP was already sitting at the intersection of metabolic and vascular risk before this study added a brain pathway to the list.

Nearly 1,200 Adults and Two Mouse Models Built the Case

The strength of this study comes from combining four separate lines of evidence rather than resting on one. Researchers measured plasma ImP in 1,196 cognitively unimpaired adults (average age 61) enrolled in two long-running Wisconsin Alzheimer's studies, then tracked how those levels lined up with cognitive test scores and blood markers including pTau-217 (a marker of the tau protein tangles seen in Alzheimer's) and neurofilament light chain (a general marker of nerve-cell damage). A related substudy sequenced gut bacteria DNA from 294 stool samples and identified a dozen bacterial species, including Eggerthella lenta, two Streptococcus species, and several Sutterella and Adlercreutzia species, carrying the gene for the ImP-producing enzyme. To test whether the link was more than a coincidence, the team used a genetic method called Mendelian randomization, which uses naturally occurring gene variants as a stand-in for a controlled experiment. They found a gene variant sitting inside the SLC6A13 gene, carried by roughly 43% of participants with European ancestry, that raises ImP levels and is also tied to modestly higher Alzheimer's risk. Finally, mice given ImP in their drinking water for months developed more amyloid plaques, more tau hyperphosphorylation, and a leakier blood-brain barrier than untreated littermates, giving the human correlations a mechanism to point to. A companion analysis from the same research group reported the same pattern between plasma ImP and cognitive scores in an overlapping set of participants.

What This Could Mean if You're Managing Your Own Gut and Brain Health

This research does not yet translate into a specific supplement, test, or diet change worth adopting, but it does sharpen what is worth raising with a doctor. If you already manage insulin resistance, obesity, or high blood pressure, this is one more reason those conditions carry weight for brain health, since ImP was elevated in those same groups before this study linked it to Alzheimer's pathology directly. Commercial gut microbiome tests do not currently report ImP levels or urdA-carrying bacteria, so there is no consumer test to act on yet, and no probiotic, supplement, or diet has been shown to lower Alzheimer's risk through this pathway. What is reasonable to raise with a doctor, if it applies to you, is how the metabolic conditions ImP already tracks with, like diabetes, hypertension, and kidney disease, are being managed, since addressing those may matter here too even without a direct ImP-lowering treatment yet.

The Open Questions This Study Leaves Unanswered

The biggest limitation is that every mouse experiment in this study used only male mice, so whether ImP damages the female brain the same way has not been directly tested, even though the human data, which included both sexes, showed similar patterns across men and women. The human cohort was also made up mostly of cognitively unimpaired adults studied at single points in time, which limits how strongly the cognition and biomarker relationships alone can prove cause and effect, a gap the genetic analysis was specifically designed to help close. ImP itself was measured on a relative scale using an untargeted metabolomics platform rather than as an absolute concentration, so the exact size of the effects will need confirmation with more precise lab methods. And the mice in this study received ImP dissolved in their drinking water rather than produced naturally by their own gut bacteria, which may not perfectly mirror how the compound behaves when it is generated and absorbed inside a real gut.

Researchers Are Already Hunting for Ways to Block It

The research team's next step is looking for ways to blunt ImP, either by targeting the bacterial enzyme that makes it or the pathway it uses to damage brain cells, rather than trying to eliminate the bacteria that produce it. In comments to the University of Wisconsin-Madison's own coverage of the study, senior researcher Barbara Bendlin said an inhibitor targeting this pathway could hopefully reduce Alzheimer's risk and slow cognitive decline for a meaningful number of people, comparing the long-term goal to how statins target cholesterol. Co-author Federico Rey noted that a microbe does not have to be abundant in the gut to have an outsized impact on its host, which is part of why ImP-producing bacteria could be a viable target even though none of the species identified so far dominate the gut microbiome.

Common Questions

What is imidazole propionate and where does it come from? It is a small molecule made by specific gut bacteria when they break down histidine, an amino acid found in protein-rich foods, using an enzyme called urocanate reductase.

Does diet raise or lower imidazole propionate levels? This study did not test diet interventions directly, but since ImP comes from bacterial breakdown of dietary histidine, both what you eat and which bacteria live in your gut plausibly affect your levels; the specific dietary levers have not been established yet.

Was this study only done in mice? No. It combined a nearly 1,200-person human cohort, a genetic analysis testing for causality, and mouse experiments; the mouse work is what showed ImP could directly cause brain damage rather than just track alongside it.

Can I get my imidazole propionate levels tested right now? Not through routine clinical or consumer microbiome tests. The levels reported in this study came from a research-grade metabolomics platform not currently offered as a standard test.

References

1. Vaibhav Vemuganti, Jea Woo Kang, Qijun Zhang, et al. (2026). Gut bacterial metabolite imidazole propionate potentiates Alzheimer’s disease pathology. Nature Communications. https://doi.org/10.1038/s41467-026-74744-z
2. Ara Koh, Antonio Molinaro, Marcus Ståhlman, et al. (2018). Microbially Produced Imidazole Propionate Impairs Insulin Signaling through mTORC1. Cell. https://doi.org/10.1016/j.cell.2018.09.055
3. Imidazole propionate is increased in diabetes and associated with dietary patterns and altered microbial ecology. Nature. https://www.nature.com/articles/s41467-020-19589-w
4. Plasma Levels of the Gut Bacteria-Derived Metabolite Imidazole Propionate Are Negatively Associated with Cognitive Scores. NIH. https://pmc.ncbi.nlm.nih.gov/articles/PMC12788820/
5. Researchers identify new target in the gut for reducing Alzheimer's risk. news.wisc.edu. https://news.wisc.edu/researchers-identify-new-target-in-the-gut-for-reducing-alzheimers-risk/